New interpretability approaches raise regulatory confidence, Simulations Plus asserts

New interpretability approaches raise regulatory confidence, Simulations Plus asserts
Simulations Plus on model interpretability

Simulations Plus draws attention to the vital role of interpretability in model evaluation for the pharmaceutical and life sciences sectors.

Sandra Suarez-Sharp, a leading authority on model validation, examines how interpretability supports regulatory confidence. Her insights explore methods for evaluating covariates, establishing biological plausibility, and extrapolating findings to new populations and dosing regimens—core issues in drug development. The company emphasizes that clarity in model outputs is increasingly seen as critical by both industry stakeholders and regulators.

Simulations Plus has previously cautioned that regulatory decisions depend on credible, transparent modeling. The company also launched QSP Flex to enable the integration of validated QSP models into major analytics platforms. Recent initiatives reflect Simulations Plus’s continued focus on verifiable model outputs in drug development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.